Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CA102N Monotherapy and Combined with LONSURF in Advanced Solid Tumors
NCT03616574Phase 1Completed
- Sponsor
- Holy Stone Healthcare Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Feb 2022
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ca102n in solid tumor and colorectal cancer (CRC) (3 arms), sponsored by Holy Stone Healthcare Co., Ltd. Primary endpoint: Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0. Started Apr 2019; status: completed.
02
Drugs
ca102n
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03616574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616574.